These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35084461)

  • 1. Glycogen synthase downregulation rescues the amylopectinosis of murine RBCK1 deficiency.
    Nitschke S; Sullivan MA; Mitra S; Marchioni CR; Lee JPY; Smith BH; Ahonen S; Wu J; Chown EE; Wang P; Petković S; Zhao X; DiGiovanni LF; Perri AM; Israelian L; Grossman TR; Kordasiewicz H; Vilaplana F; Iwai K; Nitschke F; Minassian BA
    Brain; 2022 Jul; 145(7):2361-2377. PubMed ID: 35084461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses.
    Mitra S; Chen B; Shelton JM; Nitschke S; Wu J; Covington L; Dear M; Lynn T; Verma M; Nitschke F; Fuseya Y; Iwai K; Evers BM; Minassian BA
    Acta Neuropathol; 2024 Feb; 147(1):46. PubMed ID: 38411740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to lafora bodies and the accumulation of insoluble laforin.
    DePaoli-Roach AA; Tagliabracci VS; Segvich DM; Meyer CM; Irimia JM; Roach PJ
    J Biol Chem; 2010 Aug; 285(33):25372-81. PubMed ID: 20538597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycogen hyperphosphorylation underlies lafora body formation.
    Turnbull J; Wang P; Girard JM; Ruggieri A; Wang TJ; Draginov AG; Kameka AP; Pencea N; Zhao X; Ackerley CA; Minassian BA
    Ann Neurol; 2010 Dec; 68(6):925-33. PubMed ID: 21077101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Kasiri S; Guisso DR; Wu J; Dear M; Verhalen B; Minassian BA
    Neurotherapeutics; 2022 Apr; 19(3):982-993. PubMed ID: 35347645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laforin targets malin to glycogen in Lafora progressive myoclonus epilepsy.
    Mitra S; Chen B; Wang P; Chown EE; Dear M; Guisso DR; Mariam U; Wu J; Gumusgoz E; Minassian BA
    Dis Model Mech; 2023 Jan; 16(1):. PubMed ID: 36511140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
    Gumusgoz E; Guisso DR; Kasiri S; Wu J; Dear M; Verhalen B; Nitschke S; Mitra S; Nitschke F; Minassian BA
    Neurotherapeutics; 2021 Apr; 18(2):1414-1425. PubMed ID: 33830476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lafora disease: Current biology and therapeutic approaches.
    Mitra S; Gumusgoz E; Minassian BA
    Rev Neurol (Paris); 2022 Apr; 178(4):315-325. PubMed ID: 34301405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in lafora progressive myoclonus epilepsy.
    Delgado-Escueta AV
    Curr Neurol Neurosci Rep; 2007 Sep; 7(5):428-33. PubMed ID: 17764634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laforin-malin complex degrades polyglucosan bodies in concert with glycogen debranching enzyme and brain isoform glycogen phosphorylase.
    Liu Y; Zeng L; Ma K; Baba O; Zheng P; Liu Y; Wang Y
    Mol Neurobiol; 2014 Apr; 49(2):645-57. PubMed ID: 24068615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased laforin and laforin binding to glycogen underlie Lafora body formation in malin-deficient Lafora disease.
    Tiberia E; Turnbull J; Wang T; Ruggieri A; Zhao XC; Pencea N; Israelian J; Wang Y; Ackerley CA; Wang P; Liu Y; Minassian BA
    J Biol Chem; 2012 Jul; 287(30):25650-9. PubMed ID: 22669944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laforin is required for the functional activation of malin in endoplasmic reticulum stress resistance in neuronal cells.
    Zeng L; Wang Y; Baba O; Zheng P; Liu Y; Liu Y
    FEBS J; 2012 Jul; 279(14):2467-78. PubMed ID: 22578008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion.
    Chambers JK; Thongtharb A; Shiga T; Azakami D; Saito M; Sato M; Morozumi M; Nakayama H; Uchida K
    Vet Pathol; 2018 Jul; 55(4):543-551. PubMed ID: 29444631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laforin prevents stress-induced polyglucosan body formation and Lafora disease progression in neurons.
    Wang Y; Ma K; Wang P; Baba O; Zhang H; Parent JM; Zheng P; Liu Y; Minassian BA; Liu Y
    Mol Neurobiol; 2013 Aug; 48(1):49-61. PubMed ID: 23546741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intracerebroventricular administration of alglucosidase alfa in two mouse models of Lafora disease: Relevance for clinical practice.
    Zafra-Puerta L; Colpaert M; Iglesias-Cabeza N; Burgos DF; Sánchez-Martín G; Gentry MS; Sánchez MP; Serratosa JM
    Epilepsy Res; 2024 Feb; 200():107317. PubMed ID: 38341935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy.
    Chan EM; Ackerley CA; Lohi H; Ianzano L; Cortez MA; Shannon P; Scherer SW; Minassian BA
    Hum Mol Genet; 2004 Jun; 13(11):1117-29. PubMed ID: 15102711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired malin expression and interaction with partner proteins in Lafora disease.
    Skurat AV; Segvich DM; Contreras CJ; Hu YC; Hurley TD; DePaoli-Roach AA; Roach PJ
    J Biol Chem; 2024 May; 300(5):107271. PubMed ID: 38588813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy.
    Lohi H; Ianzano L; Zhao XC; Chan EM; Turnbull J; Scherer SW; Ackerley CA; Minassian BA
    Hum Mol Genet; 2005 Sep; 14(18):2727-36. PubMed ID: 16115820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lafora progressive myoclonus epilepsy: NHLRC1 mutations affect glycogen metabolism.
    Couarch P; Vernia S; Gourfinkel-An I; Lesca G; Gataullina S; Fedirko E; Trouillard O; Depienne C; Dulac O; Steschenko D; Leguern E; Sanz P; Baulac S
    J Mol Med (Berl); 2011 Sep; 89(9):915-25. PubMed ID: 21505799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal glycogen chain length pattern, not hyperphosphorylation, is critical in Lafora disease.
    Nitschke F; Sullivan MA; Wang P; Zhao X; Chown EE; Perri AM; Israelian L; Juana-López L; Bovolenta P; Rodríguez de Córdoba S; Steup M; Minassian BA
    EMBO Mol Med; 2017 Jul; 9(7):906-917. PubMed ID: 28536304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.